As the demand for weight-loss solutions surges, online sales of obesity drug alternatives have entered a new phase—testing the boundaries of regulatory restrictions. These alternatives, often produced by compounding pharmacies and telehealth companies, gained traction amid past shortages of branded GLP-1 drugs like Wegovy and Zepbound. But with manufacturers now meeting demand, the legal landscape for these substitutes is shifting.
Compounding pharmacies, authorized under U.S. Food and Drug Administration (FDA) rules to replicate branded drugs during shortages, initially filled the supply gap by producing versions of medications like semaglutide and tirzepatide. Companies like Orderly Meds even advertised “personalized” formulations adding supplements like B-12 to avoid direct replication. However, the FDA’s guidance clarifies that minor tweaks—such as dosage changes or additive ingredients—don’t exempt products from regulations banning “essentially identical” copies of approved drugs, unless a prescriber confirms clinical necessity for individual patients.
With shortages resolved, compounding pharmacies’ grace period expired in spring, prompting some to halt production. Yet firms like Orderly Meds and Hims continue selling compounded versions, navigating a gray area. Hims, for instance, now offers both branded Wegovy and compounded semaglutide online, planning to reduce but not eliminate compounded sales by focusing on personalized dosages. Data shows that while only one outsourcing facility reported producing semaglutide in early 2023, ten did so by late 2024—highlighting the market’s scale despite regulatory ambiguity.
A bigger concern lies in imported active ingredients, mostly from China, used in compounded drugs. Though legal, these ingredients aren’t strictly vetted for safety, as compounding facilities aren’t required to meet the same standards as branded drug manufacturers. “There’s no established quality bar for these compounds,” notes Marta Wosinska, a healthcare economist, warning that unregulated ingredients pose undisclosed risks.
Branded drugmakers are also adapting: Lilly will offer cash-paying patients its highest-dose Zepbound vials for $499/month starting July, undercutting some compounded alternatives. This move, alongside FDA enforcement efforts, signals a tightening noose around unregulated substitutes. Yet with obesity rates rising and demand for affordable solutions persistent, the clash between market innovation and regulatory oversight will define this sector’s future—leaving consumers to weigh convenience against safety in a landscape still shaped by legal uncertainty.
Related topics:
